Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 9;11(1):53.
doi: 10.1038/s41523-025-00745-8.

Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention

G Aurilio  1 , D Serrano  1 , M Lazzeroni  1 , A Guerrieri-Gonzaga  1 , H Johansson  1 , S Gandini  2 , I M Briata  3 , M D'Amico  3 , S Spinaci  4 , P Veronesi  5   6 , V Galimberti  5 , M Intra  5 , B M Heckman-Stoddard  7 , E Szabo  7 , G Viale  8   9 , B Bonanni  1 , A DeCensi  10
Affiliations
Review

Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention

G Aurilio et al. NPJ Breast Cancer. .

Abstract

Window-of-opportunity trials are a path to screen effective agents and optimize dose in breast cancer risk reduction. We review the scientific evidence regarding the utility of window-of-opportunity trials to screen effective agents and optimize dose for successful risk reduction/interception of breast cancer. Low-dose tamoxifen was evaluated in a window-of-opportunity trial and then validated in a phase-III trial. We are now studying similar activity with low-dose exemestane.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. The WOO model reveals the field cancerization effect and may be relevant to preventive therapy.
A WOO study exploits the presence of a mammary field cancerization to draw signals on cancer tissue biomarker changes (red circles) and on adjacent pre-cancer lesions including DCIS/LCIS and ADH (blue circles). A main objective of a WOO study is to measure Ki-67 LI and percentage of precancer lesions to draw preventive activity of drugs.
Fig. 2
Fig. 2. Key points summarizing current evidence and strategies in endocrine prevention of breast cancer.
This figure outlines major concepts in endocrine prevention for high-risk breast cancer women. Topics include the clinical benefit and challenges of endocrine preventive therapy (A), dose optimization through window-of-opportunity trials (B), the role of Ki-67 LI as a prognostic biomarker (C), guideline-approved use of low-dose tamoxifen (D), novel dosing schedules of exemestane (E), and the FDA's project Optimus for dose selection standardization (F).
See this image and copyright information in PMC

References

    1. Sporn, M. B. Carcinogenesis and cancer: different perspectives on the same disease. Cancer Res.51, 6215–6218 (1991). - PubMed
    1. Cuzick, J. et al. Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial. Lancet Oncol.25, 108–116 (2024). - DOI - PubMed
    1. Goss, P. E. et al. Exemestane for breast-cancer prevention in postmenopausal women. N. Engl. J. Med.364, 2381–2391 (2011). - DOI - PubMed
    1. Cuzick, J. et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet381, 1827–1834 (2013). - DOI - PMC - PubMed
    1. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71, 209–249 (2021). - DOI - PubMed

LinkOut - more resources